<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01364701</url>
  </required_header>
  <id_info>
    <org_study_id>0449-10-RMB</org_study_id>
    <nct_id>NCT01364701</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Effectiveness of 2 Lower Dose Combined PDE5i's Versus Single Maximal Dose PDE5i Treatment</brief_title>
  <acronym>PDE5i</acronym>
  <official_title>A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical effectiveness is of the finest tools to evaluate treatment success and is combined
      of 3 elements: treatment effectivity, side effect profile and patient compliance. Since the 3
      main PDE5i's differ in their molecular structure, therapeutic profile and pharmacokinetics,
      it seems logical to assume that combining 2 different PDE5i's at lower dosage each may be
      beneficial in comparison to a single PDE5i maximal dose therapy. The aim of this study is to
      compare the clinical effectiveness of combination therapy (2 lower-dose PDE5i's) versus
      single maximal dose PDE5i therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, randomized, 3-arm parallel trial on 60 males with erectile
      dysfunction (ED) that have never been exposed to PDE5i therapy (naïve patients) will be
      enrolled. In each group, every patient will receive three treatment regimes (Viagra®50mg &amp;
      Cialis®10mg, Viagra®100mg, Cialis®20mg), in different sequences of administration.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Index of Erectile Function-Erectile Dysfunction (IIEF-ED) Domain Score</measure>
    <time_frame>Every visit- altogether 3 months</time_frame>
    <description>At each visit after use of different treatment each time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erection Hardness Scale</measure>
    <time_frame>Each visit- altogether 3 months</time_frame>
    <description>At each visit after use of different treatment each time</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Maximal dose sildenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 tablets of sildenafil 100mg are given for on demand use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tadalafil 20mg maximal dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 tablets of tadalafil 20mg are given for on demand use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination half dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 tablets of sildenafil 50mg and tadalafil 10mg are given for on demand use</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil 100 mg</intervention_name>
    <description>4 tablets for on demand use</description>
    <arm_group_label>Maximal dose sildenafil</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil 20 mg</intervention_name>
    <description>4 tablets on demand</description>
    <arm_group_label>Tadalafil 20mg maximal dose</arm_group_label>
    <other_name>Cialis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination half of maximal dose for sildenafil &amp; tadalafil</intervention_name>
    <description>4 tablets on demand</description>
    <arm_group_label>Combination half dose</arm_group_label>
    <other_name>Combination</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ranging between 35-75 years.

          -  Sexually active

          -  IIEF ED domain score 22 and below

        Exclusion Criteria:

          -  Subjects with premature ejaculation as their main sexual complaint.

          -  Subjects with severe cardiovascular disease

          -  Subjects with Contraindications to PDE5i therapy. Namely patients receiving treatment
             with nitrate based medication or patients that for various reasons cannot take PDE5
             inhibitors (i.e severe coronary disease, liver or renal failure, concomitant
             medications, etc.).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoram Vardi, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilan Gruenwald, MD</last_name>
    <phone>0097248542882</phone>
    <email>i_gruenwald@rambam.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoram Vardi, Prof.</last_name>
    <phone>0097248542819</phone>
    <email>yvardi@rambam.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ilan Gruenwald, MD</last_name>
      <phone>0097248542882</phone>
      <email>i_gruenwald@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2011</study_first_posted>
  <last_update_submitted>June 17, 2011</last_update_submitted>
  <last_update_submitted_qc>June 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ilan Gruenwald MD</name_title>
    <organization>Rambam Health Care Campus</organization>
  </responsible_party>
  <keyword>Erectile dysfunction</keyword>
  <keyword>combination therapy</keyword>
  <keyword>Sildenafil</keyword>
  <keyword>tadalafil</keyword>
  <keyword>PDE5i</keyword>
  <keyword>No Conditions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

